Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Learn why financial planning is crucial for achieving long-term financial stability. Don't leave your future to chance—plan wisely.
23,497 articlesA major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Offerpad rolls out two internal AI platforms, SCOUT and HENRY, as the company pursues 1,000 quarterly home transactio...
A focused look at a $7 million wager on a CNS drug maker in Phase 3. Learn what this move signals about biotech momen...
China’s export engine and structural advantages are shaping a landscape where trade deals matter less than the decade...
Block, Palantir, Atlassian, and Salesforce are in the spotlight as layoffs and hiring pauses test how cost cuts affec...
When a big investor deploys tens of millions into a biotech name ahead of an FDA decision, it can signal strong convi...
A prompt-driven AI nicknamed Grok projects sharp gains for XRP, Bitcoin, and Ethereum by late 2026, even as oil-drive...
A conflict over Iran threatens Asia's access to fertilizer and helium, risking farm yields and semiconductor supply c...
A global four-week contest stitches together AI personas, crypto rewards, and influencer intrigue. Here’s how fake in...
Both ServiceNow and Salesforce fell roughly 5% on the latest trading session as AI licensing concerns rattled investo...
Oil’s surge fuels a wave of gains in key energy ETFs, led by XLE, OIH, and PBT, as supply, demand, and drilling budge...
As geopolitical tensions flare and oil costs surge, recession odds jump higher. Moody's Analytics now grids a near-50...